Print Page   |   Contact Us   |   Sign In   |   Join
Business Wire Life Sciences News (US)
Share |

Desert Clinics “Center of Excellence” Reducing Chronic PainOpen in a New Window

RANCHO MIRAGE, Calif.--(BUSINESS WIRE)--Along the Coachella Valley, from Palm Springs to Rancho Mirage and Indio, doctors at three healthcare clinics are changing the lives of patients in pain. Physicians, medical professionals, and the Desert Clinic Pain Institute and the Center of Excellence (COE) run a three-phase, 12-month program to reduce the suffering of patients in acute and chronic pain. “Our goal is to treat patients in chronic pain, using a comprehensive, integrated and holistic meth


FDA Approves Soliris® (Eculizumab) for the Treatment of Patients with Generalized Myasthenia Gravis (gMG)Open in a New Window

NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the U.S. Food and Drug Administration (FDA) has approved Soliris® (eculizumab) as a treatment for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody-positive. In the Phase 3 REGAIN study and its ongoing open-label extension study, Soliris demonstrated treatment benefits for patients with anti-AchR antibody-positive gMG who had previously fa


Proton OnSite Has Been Awarded a Contract for Approximately USD 1.8 Million and Assumes the Lead Role in the US Government Advanced Water Splitting Benchmarking ProjectOpen in a New Window

WALLINGFORD, Conn.--(BUSINESS WIRE)--#DOE--Proton OnSite awarded contract for approximately USD 1.8 million - assumes lead role in US Government Advanced Water Splitting Benchmark Project.


New Yes on Issue 2 Ad Lands KO Punch against Bully Drug CompaniesOpen in a New Window



Blink Health to Continue Providing Affordable Access to Patients Currently Using Blink Health’s Service at CVS PharmaciesOpen in a New Window

NEW YORK--(BUSINESS WIRE)--Blink Health is working with customers affected by CVS Health’s decision to cut off access to Blink Health at CVS pharmacies.


Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)Open in a New Window

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)


AOC and AHF to Join Forces in North TexasOpen in a New Window

FORT WORTH, Texas--(BUSINESS WIRE)--AOC & AHF to Join Forces in North Texas - New affiliation between AIDS Outreach Center & AIDS Healthcare Foundation seeks to improve HIV/AIDS services


Anika Announces the Forthcoming Appointment of Thomas M. Finnerty as Chief Human Resources OfficerOpen in a New Window

BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the appointment of Thomas M. Finnerty as its Chief Human Resources Officer. Mr. Finnerty brings a 25-year track record of building global human resources teams, and specializes in talent acquisition and development, executive coaching, and employee engagement. After sp


High Demand from Nutraceutical Segment to Boost the Saffron Market | TechnavioOpen in a New Window

LONDON--(BUSINESS WIRE)--#Food--According to the latest market study released by Technavio, the global saffron market is expected to grow at a CAGR of close to 6% from 2017-2021.


Stryker’s Spine Division to Launch Tritanium® C Anterior Cervical Cage at NASS 2017Open in a New Window

ALLENDALE, N.J.--(BUSINESS WIRE)--Stryker Spine will introduce its Tritanium C Anterior Cervical Cage at the NASS 2017 Annual Meeting, Oct. 25–28, in Orlando, Fla. (booth No. 500)


Tenet Diagnostics Recommends Genomic Testing to Assess Cancer Risks: Employers & Payers Optimize Clinical Outcomes, Improve Member SatisfactionOpen in a New Window

KENILWORTH, N.J.--(BUSINESS WIRE)--Tenet Diagnostics recommends genomic testing to assess cancer risks: employers & payers optimize clinical outcomes, improve member satisfaction.


Brookline Capital Markets Launches Biotechnology Sector Research CoverageOpen in a New Window

NEW YORK--(BUSINESS WIRE)--Brookline Capital Markets, a fast-growing investment bank to emerging healthcare companies, announced the launch of research coverage in the biotechnology sector. Brookline’s coverage is being led by Kumar Raja, Ph.D., Senior Biotechnology Analyst on the firm’s equity research team. The companies include: *Corbus Pharmaceuticals (CRBP) *Medicenna Therapeutics Corp (MDNA) *VBI Vaccines (VBIV) Kumar Raja, joins Brookline from Noble Life Science Partners and prior to tha


E Ink and LTS Partner to Develop Smart Patch to Improve Medical ManagementOpen in a New Window

BILLERICA, Mass.--(BUSINESS WIRE)--E Ink Holdings, "E Ink" (8069.TW), the leading innovator of electronic ink technology and LTS Lohmann-Therapie Systeme AG, “LTS” leading in the development and manufacturing of transdermal therapeutic systems, today announced their partnership to develop a “Smart Patch” prototype. The Smart Patch prototype is a transdermal therapeutic system (TTS) that delivers medication to patients in a convenient, controlled and comfortable manner and features an E Ink disp


BusinessOne Technologies and Stotle Partner to Accelerate Managed Markets Strategic Insights and Decision-MakingOpen in a New Window

BENSALEM, Pa.--(BUSINESS WIRE)--BusinessOne Technologies and Stotle partner to streamline, speed analysis of managed markets access data across healthcare business units.


Leading pharmaceutical executive Dr. Robert Karr joins Verseon’s Board of DirectorsOpen in a New Window

FREMONT, Calif.--(BUSINESS WIRE)--Leading pharmaceutical executive and biotech entrepreneur Dr. Robert W. Karr was recently elected as a Non-Executive Director of Verseon.


Physicians’ Education Resource® to Offer EACCME® Accreditation for European Biosimilars Live WebcastOpen in a New Window

CRANBURY, N.J.--(BUSINESS WIRE)--Physicians’ Education Resource® to Offer EACCME® Accreditation for European Biosimilars Live Webcast


QPharma Introduces CRM System for Life SciencesOpen in a New Window

MORRISTOWN, N.J.--(BUSINESS WIRE)--#CRM--QPharma has announced the launch of Ti Force™, a new, cloud-based mobile CRM system developed specifically for the life sciences industry.


Collaborative Clinical Study Aims to Advance Treatment of Kidney and Prostate Cancer with 3D PrintingOpen in a New Window

MINNEAPOLIS & REHOVOT, Israel--(BUSINESS WIRE)--Stratasys (NASDAQ: SSYS), a global leader in applied additive technology solutions, today announced a new clinical study is being conducted with the New York University (NYU) School of Medicine – aimed at advancing diagnosis and treatment of complex kidney and prostate tumors through imaging and 3D printing. These patient-specific 3D models of organs and their associated pathologies may empower surgeons and researchers to conduct more accurate pre


Immune Pharmaceuticals Inc. Announces Closing of $18,000,000 Public Offering of Convertible Preferred Stock and WarrantsOpen in a New Window

ENGLEWOOD CLIFFS, N.J.--(BUSINESS WIRE)--Immune Pharmaceuticals Inc. (“Immune”) (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced the closing of its previously announced public offering of units for gross proceeds of $18,000,000, which excludes underwriting discounts and commissions and offering expenses payable by Immune. The offering was comprised of units, priced at a public offering pric


Powering Precision Health Summit Founder and Chairman Kevin Hrusovsky to Fuel Precision Health Movement with Keynote AddressOpen in a New Window

BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--#PPH--Powering Precision Health Summit Founder and Chairman Kevin Hrusovsky to Fuel Precision Heath Movement with Keynote Address


Knopp Biosciences Announces Renewal of NIH Blueprint Grant Award for Advancing KCNQ2 Modulators in EpilepsyOpen in a New Window

PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC today announced the renewal and expansion of its grant award from the National Institutes of Health Blueprint Neurotherapeutics Network to advance novel treatments for epilepsy. The Phase 2 award under the NIH Small Business Innovation Research (SBIR) program anticipates NIH support of up to $2 million over the next three years of the project, subject to satisfactory completion of milestones. The renewal follows the successful completion of all


FzioMed Receives FDA Approval for Small Confirmatory Study of Oxiplex® in Patients Undergoing Lumbar Surgery for Disc HerniationOpen in a New Window

SAN LUIS OBISPO, Calif.--(BUSINESS WIRE)--FzioMed, Inc., a biomaterials company, has received approval from FDA to conduct a small confirmatory study of Oxiplex in the U.S.


City of Hope’s Annual Walk For Hope Once Again Brings Together Thousands to Fight Women’s CancersOpen in a New Window

DUARTE, Calif.--(BUSINESS WIRE)--Breast cancer patient Kaye McDonald will walk beside 10,000 supporters to help raise awareness for women’s cancers at City of Hope’s Walk for Hope.


Anthem and Wharton Launch Collaboration to Study and Pilot New Health Care IdeasOpen in a New Window

INDIANAPOLIS & PHILADELPHIA--(BUSINESS WIRE)--#behavioraleconomics--Anthem, Inc. and the Wharton School of the University of Pennsylvania announce a collaboration to study and pilot new ideas to improve health care.


Investing in U.S. UniversitiesOpen in a New Window

PALO ALTO, Calif.--(BUSINESS WIRE)--Bosch recently hosted the first symposium of energy researchers supported by the Bosch Energy Research Network. BERN also awarded six energy research grants to researchers at five leading U.S. universities and awarded energy internships to 18 students. At the symposium 14 university research faculty presented and discussed research results on battery, powertrain, and energy conversion and management topics with Bosch engineers from across North America and Ge


OncLive® Welcomes New Members to the Advisory Board for Giants of Cancer Care®Open in a New Window

CRANBURY, N.J.--(BUSINESS WIRE)--OncLive® Welcomes New Members to the Advisory Board for Giants of Cancer Care®


WINS Act Will Promote and Expand Innovation in WisconsinOpen in a New Window

MADISON, Wis.--(BUSINESS WIRE)--BioForward supports WINS Act legislation to provide resources to advance, innovate and support Wisconsin’s growing industry clusters.


For Second Year in a Row, KelseyCare Advantage Awarded 5 Stars by the Centers for Medicare & Medicaid Services (CMS)Open in a New Window

HOUSTON--(BUSINESS WIRE)--KelseyCare Advantage, a Medicare Advantage plan offered in the Houston-area, earned five out of five stars in an annual assessment by CMS.


Invacare Corporation to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial ResultsOpen in a New Window

ELYRIA, Ohio--(BUSINESS WIRE)--Invacare Corporation to host conference call and webcast to discuss third quarter 2017 financial results


Integrity Applications Announces Strategic Corporate UpdateOpen in a New Window

WILMINGTON, Del. & ASHDOD, Israel--(BUSINESS WIRE)--Integrity Applications Announces Strategic Corp Update; Near-term Priorities Include GlucoTrack Commercialization in Europe and GlucoTrack US FDA Approval


QB3 Signs Partnership with Science Exchange, Giving Early Stage Life Science Companies Access to More than 2,500 Qualified Scientific Service ProvidersOpen in a New Window

PALO ALTO, Calif.--(BUSINESS WIRE)--Science Exchange, a platform for outsourced research and development (R&D) services, today announced a partnership with QB3, the University of California hub for innovation and entrepreneurship for life sciences. Through an exclusive Science Exchange-QB3 marketplace, QB3-affiliated companies will now have access to a customized and secure marketplace where they can instantly order R&D services from a network of more than 2,500 qualified scientific ser


Vantari Genetics and Translational Software Partner to Deliver Genotyping Services for Banner Alzheimer’s InstituteOpen in a New Window

IRVINE, Calif. & BELLEVUE, Wash.--(BUSINESS WIRE)--Vantari Genetics and Translational Software Partner to Deliver Genotyping Services for Banner Alzheimer’s Institute


Long-Term Safety of Textured and Smooth Breast Implants ReviewedOpen in a New Window

MARINA DEL REY, Calif.--(BUSINESS WIRE)--#ASAPS--The long-term safety of textured and smooth breast implants was reported in Aesthetic Surgery Journal by Dr. Grant Stevens, et al.


Vertex Doubles Scholarship Program to Support the Academic and Professional Advancement of People Living with Cystic Fibrosis and Their FamiliesOpen in a New Window

BOSTON--(BUSINESS WIRE)--Vertex Doubles Scholarship Program to Support the Academic and Professional Advancement of People Living with Cystic Fibrosis and Their Families


Cerus Announces National German Reimbursement for Pathogen Inactivated PlateletsOpen in a New Window

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that the Institute for the Hospital Remuneration System (Institut für das Entgeltsystem im Krankenhaus, or InEK) in Germany will include pathogen-inactivated platelets for national reimbursement starting January 1, 2018. Pathogen-inactivated platelets will be reimbursed through ZE (Zusatzentgelte) codes 164 and 165 and cover both platelet collection methods currently in use in Germany, apheresis and whole blood de


Enzo Biochem Announces NYS Department of Health’s Approval of a New Women’s Health Infectious Disease PanelOpen in a New Window

NEW YORK--(BUSINESS WIRE)--Enzo Biochem Inc. (NYSE:ENZ) today announced it has received approval of another women’s health infectious disease diagnostic panel, which when combined with the Company’s previously approved panels, makes for one of the most comprehensive, efficient and affordable diagnostic products and services on the market today. A variety of infections, including sexually transmitted ones, are detected from a single vaginal swab collection via the Company’s proprietary, versatil


Quidel Receives FDA Clearance for Its Point-of-Care Sofia® Lyme FIAOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market its Sofia Lyme FIA for the rapid differential detection of human IgM and IgG antibodies to Borrelia burgdorferi from serum and plasma specimens from patients suspected of B. burgdorferi in


Exactech Enters Definitive Agreement with TPG Capital to Go PrivateOpen in a New Window

GAINESVILLE, Fla.--(BUSINESS WIRE)--Exactech (Nasdaq: EXAC), a leading developer and producer of orthopaedic implant devices and surgical instrumentation for extremities and large joints, today announced that it has entered into a definitive merger agreement under which TPG Capital, the global private equity platform of alternative asset firm TPG, will acquire all of the outstanding shares of Exactech common stock. Exactech’s board of directors approved the agreement which provides for the paym


Surmodics Announces First Patient Enrolled in TRANSCEND Pivotal Clinical Trial for SurVeil® Drug-Coated BalloonOpen in a New Window

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics today announced enrollment of the first patient in TRANSCEND, the pivotal clinical trial for the SurVeil drug-coated balloon.


New Clinical Data Presented at the World Congress of Gastroenterology @ ACG 2017 Shows Increased Dysplasia Detection Using Volumetric Laser Endomicroscopy with Laser MarkingOpen in a New Window

BEDFORD, Mass.--(BUSINESS WIRE)--New Clinical Data Presented at the World Congress of Gastroenterology Shows Increased Dysplasia Detection Using Volumetric Laser Endomicroscopy


Physicians Report Early Successes Across Multiple Applications in First-in-Human Uses of GORE® SYNECOR Preperitoneal Biomaterial Hernia Repair DeviceOpen in a New Window

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--Physicians among the first to use the GORE® SYNECOR Preperitoneal Biomaterial, a unique hybrid device for hernia repair, are reporting positive experiences in using the device in a range of applications, according to W. L. Gore & Associates (Gore). The company today shared feedback from physicians focused on bariatric, hernia, and plastic surgery who have used the GORE® SYNECOR Preperitoneal Biomaterial hernia repair device since it received 510(k) clearan


Claret Medical Closes $14.5 Million in Series C Financing to Extend Successful U.S. Launch of Sentinel Cerebral Protection SystemOpen in a New Window

SANTA ROSA, Calif.--(BUSINESS WIRE)--#ProtectedTAVR--Claret Medical closes $14.5 million a Series C financing which will extend the successful U.S. launch of the Sentinel Cerebral Protection System.


Arrowhead Presents Promising Preclinical Data on Development of ARO-AAT for Treatment of Alpha-1 Liver Disease at Liver Meeting® 2017Open in a New Window

PASADENA, Calif.--(BUSINESS WIRE)--$arwr #livermtg17--Arrowhead presents data on ARO-AAT in late breaking poster at the AASLD Liver Meeting 2017


McKesson Supports Declaring Opioid Epidemic a National EmergencyOpen in a New Window

SAN FRANCISCO--(BUSINESS WIRE)--Today, John Hammergren, chairman and CEO of McKesson, issued the following statement: “McKesson supports President Trump’s indication that he intends to declare the opioid epidemic a ‘national emergency.’ This vital exercise of executive authority will provide much needed resources to help tackle the opioid crisis in new ways and with a deepened sense of urgency. There is no doubt the opioid epidemic is one of our nation’s most pressing public health crises. Its


Pilgrim Quality Solutions to Address Pharmaceutical Implications of CDER Metrics and ReportingOpen in a New Window

TAMPA, Fla.--(BUSINESS WIRE)--Pilgrim Quality Solutions, a leading global provider of enterprise quality management software and services for the Life Sciences, today announced it will present a live webcast later this month for pharmaceutical organizations on the implications of participating in the Food and Drug Administration’s (FDA) Quality Metrics reporting program. The webinar, Solutions for CDER Metrics and Reporting, on October 31, 2017, will be co-presented by Cynthia Lambert, Regulato


Clovis Oncology to Announce Third Quarter 2017 Financial Results and Host Webcast Conference Call on November 1Open in a New Window

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology to Announce Q3 2017 Financial Results and Host Webcast Conference Call on November 1


Viamet to Present Data Demonstrating the Efficacy and Safety of VT-1161 for the Treatment of Recurrent Vulvovaginal Candidiasis at ISIDOG Congress 2017Open in a New Window

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--#ISIDOG--Viamet Presenting Data Demonstrating Efficacy and Safety of VT-1161 for the Treatment of Recurrent Vulvovaginal Candidiasis at ISIDOG Congress 2017


PlayMaker Introduces PlayMaker Edge for HMEOpen in a New Window

FRANKLIN, Tenn.--(BUSINESS WIRE)--#HME--PlayMaker Edge for HME provides HME providers with a comprehensive solution to develop and successfully execute effective sales strategies.


Enanta Pharmaceuticals Announces Positive Phase 1 a/b Clinical Results for its Lead FXR Agonist, EDP-305Open in a New Window

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a chemistry-driven biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced positive results from its Phase 1 clinical study of EDP-305, Enanta’s lead FXR agonist for non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). The objective of this double-blind, placebo-controlled study in adult healthy volunteer (HV) subjects and subjec


Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease Treatments Including Phase 3 AducanumabOpen in a New Window

CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced today that the companies have expanded their existing agreement to jointly develop and commercialize investigational Alzheimer’s disease treatments. Under the terms of the agreement Eisai has exercised its option to co-develop and co-promote aducanumab, Biogen’


Finch Therapeutics and Crestovo Announce Merger to Form Finch Therapeutics Group, a Leading, Fully Integrated Microbiome CompanyOpen in a New Window

SOMERVILLE, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Finch Therapeutics, a privately held microbiome engineering company and Crestovo, a privately held, clinical-stage biopharmaceutical company, announced today the successful completion of a merger, creating a leading, fully integrated microbiome company. The new entity, Finch Therapeutics Group, combines Crestovo’s extensive IP assets and late-stage candidate for recurrent C. difficile infections, CP101, an oral Full-Spectrum Microbiota™ pro


Alpine Immune Sciences and Kite Extend Research Term of Collaboration to Create Next-Generation CAR-T and TCRsOpen in a New Window

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune diseases and cancer, today announced it has extended the research term of its worldwide research and license agreement with Kite, a Gilead (NASDAQ:GILD) company. The research collaboration and license agreement, initiated in October 2015, grants Kite an exclusive license to two Alpine programs from Alpine’s Transmembrane Immunomodulatory Protein (


US FDA Approves New Easy-to-Use, Once-Weekly BYDUREON® BCise™ Injectable Medicine for Patients with Type-2 DiabetesOpen in a New Window

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved BYDUREON® BCise™ (exenatide extended-release) injectable suspension, a new formulation of BYDUREON® (exenatide extended-release) injectable suspension in an improved once-weekly, single-dose autoinjector device for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines in addition to diet and exercise, to improve glycemic control. U


AstraZeneca and Merck Rapidly Advance LYNPARZA® (olaparib) in Japan With a Second Regulatory SubmissionOpen in a New Window

KENILWORTH, N.J.--(BUSINESS WIRE)--$MRK #MRK--AstraZeneca and Merck Rapidly Advance LYNPARZA® (olaparib) in Japan With a Second Regulatory Submission


TransEnterix Schedules Third Quarter 2017 Financial and Operating Results Conference Call for November 9, 2017Open in a New Window

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC) announced today that it plans to release third quarter 2017 financial and operating results after the market closes on Thursday, November 9, 2017. Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer will host a conference call to discuss these results starting at 4:30 pm Eastern Time the same day. The call will be concurrently webca


Corindus Evaluates Incorporating HeartFlow Technology with CorPath GRX SystemOpen in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)--Corindus to incorporate CorPath GRX System with HeartFlow® FFRct Analysis in robotic-assisted case series to optimize clinical outcomes


Saranas Invited to Present at TCT 2017 in DenverOpen in a New Window

HOUSTON--(BUSINESS WIRE)--Saranas Invited to Present its Cardiovascular Technology at TCT Conference in Denver, Oct. 31


Magellan Health to Participate in Bernstein Healthcare Services Disruptors ConferenceOpen in a New Window

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Magellan Health to participate in a fireside chat at the Bernstein Healthcare Services Disruptors Conference in Boston on Tuesday, November 14, 2017.


Institute of Human Virology Hosts 19th Annual International Meeting of Top Medical Virus Researchers in Baltimore, MarylandOpen in a New Window

BALTIMORE--(BUSINESS WIRE)--The Institute of Human Virology (IHV) at the University of Maryland School of Medicine today commenced IHV’s 19th Annual International Meeting, which will be held through Thursday, October, 26 at the Four Seasons Hotel in Baltimore, Maryland. IHV’s Annual International Meeting attracts hundreds of elite scientists who descend upon Baltimore to share ideas and inspire medical virus research collaborations. “Our meeting is designed to highlight cutting-edge science and


Hallstar’s New Photostabilizer, AvoBrite®, Solves Customers’ Regulatory Challenges While Delivering Outstanding PhotoprotectionOpen in a New Window

CHICAGO--(BUSINESS WIRE)--#AvoBrite--Hallstar's photoprotection expertise leads to launch of its latest innovation, AvoBrite®, to stabilize Avobenzone, which is also China-compliant.


Health Mart and APCI Celebrate Pharmacists on Florida Independent Pharmacy DayOpen in a New Window

LAKELAND, Fla.--(BUSINESS WIRE)--Health Mart® and APCI Celebrate Pharmacists on Florida Independent Pharmacy Day


Linde plc Amends Exchange Offer Minimum Acceptance ConditionOpen in a New Window

GUILDFORD, England--(BUSINESS WIRE)--Linde plc amends exchange offer minimum acceptance condition.


Cerveau Technologies Inc. Signs License and Supply Agreement with AbbVie for Novel Tau Imaging AgentOpen in a New Window

BOSTON--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced a license and supply agreement with AbbVie for use of [F-18]MK-6240, an investigational imaging agent to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease. The relationship is focused on the use of [F-18]MK-6240 as a


DermTech Announces Addition of Daniel M. Siegel, MD to Advisory BoardOpen in a New Window

LA JOLLA, Calif.--(BUSINESS WIRE)--#AAD--DermTech Announces Addition of past AAD President and Coding and Reimburesment Task Force member, Daniel M. Siegel, MD to its Advisory Board.


WRDS-SSRN Innovation Award Presented to University of Gothenburg at AACSB Conference in MaltaOpen in a New Window



TG1050 is Well Tolerated and Induces a Strong Specific Immune Response in Patients with Chronic Hepatitis BOpen in a New Window

STRASBOURG, France--(BUSINESS WIRE)--#HBV--Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops viral-based immunotherapies, announces that the analyses conducted on patients with chronic hepatitis B receiving standard antiviral therapies and a single dose of TG1050 in the Phase 1/1b trial, confirm the good tolerability profile and demonstrate the immunogenicity of this novel therapeutic vaccine. Transgene presented a poster describing the first promising clinical data


BioFlorida, Inc. | 6742 Forest Hill Blvd., Suite 256 | West Palm Beach, FL 33413
(P) 561-653-3839
Membership Management Software Powered by YourMembership  ::  Legal